News | July 04, 2023
Adare Pharma divests Adare Biome to dsm-firmenich
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
The VITA-FAST tokens have been met with overwhelming interest
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society
New reforestation projects in Brazil, India, Vietnam, Ghana and Rwanda in addition to existing projects including in Australia and Indonesia
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Currently there are no vaccines approved anywhere in the world for gonorrhoea, and antimicrobial resistance to existing treatments is increasing
Ensitrelvir is an oral antiviral that suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease.
Subscribe To Our Newsletter & Stay Updated
